These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 34978854)

  • 21. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC28. PubMed ID: 33646836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d.
    Sacks HS
    Ann Intern Med; 2022 Apr; 175(4):JC40. PubMed ID: 35377719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
    Kim JY; Jang YR; Hong JH; Jung JG; Park JH; Streinu-Cercel A; Streinu-Cercel A; Săndulescu O; Lee SJ; Kim SH; Jung NH; Lee SG; Park JE; Kim MK; Jeon DB; Lee YJ; Kim BS; Lee YM; Kim YS
    Clin Ther; 2021 Oct; 43(10):1706-1727. PubMed ID: 34551869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [SARS-CoV-2 neutralizing monoclonal antibodies: a potential breakthrough in the early treatment of Covid-19 in high-risk patients].
    de Bree GJ; Wiersinga WJ
    Ned Tijdschr Geneeskd; 2021 Oct; 165():. PubMed ID: 34854645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Household Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 in the United States.
    Lewis NM; Chu VT; Ye D; Conners EE; Gharpure R; Laws RL; Reses HE; Freeman BD; Fajans M; Rabold EM; Dawson P; Buono S; Yin S; Owusu D; Wadhwa A; Pomeroy M; Yousaf A; Pevzner E; Njuguna H; Battey KA; Tran CH; Fields VL; Salvatore P; O'Hegarty M; Vuong J; Chancey R; Gregory C; Banks M; Rispens JR; Dietrich E; Marcenac P; Matanock AM; Duca L; Binder A; Fox G; Lester S; Mills L; Gerber SI; Watson J; Schumacher A; Pawloski L; Thornburg NJ; Hall AJ; Kiphibane T; Willardson S; Christensen K; Page L; Bhattacharyya S; Dasu T; Christiansen A; Pray IW; Westergaard RP; Dunn AC; Tate JE; Nabity SA; Kirking HL
    Clin Infect Dis; 2021 Oct; 73(7):1805-1813. PubMed ID: 33185244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).
    Irfan N; Chagla Z
    Ann Intern Med; 2021 May; 174(5):JC50. PubMed ID: 33939483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WHO provides 2 conditional recommendations for casirivimab-imdevimab combination therapy in COVID-19.
    Dunne C; Lang E
    Ann Intern Med; 2022 Jan; 175(1):JC6. PubMed ID: 34871050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection.
    Bruzzesi E; Ranzenigo M; Castagna A; Spagnuolo V
    New Microbiol; 2021 Jul; 44(3):135-144. PubMed ID: 34783348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.
    Jing QL; Liu MJ; Zhang ZB; Fang LQ; Yuan J; Zhang AR; Dean NE; Luo L; Ma MM; Longini I; Kenah E; Lu Y; Ma Y; Jalali N; Yang ZC; Yang Y
    Lancet Infect Dis; 2020 Oct; 20(10):1141-1150. PubMed ID: 32562601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In non-critically ill patients with COVID-19, therapeutic anticoagulation improved survival to discharge without organ support.
    Donato AA
    Ann Intern Med; 2021 Dec; 174(12):JC134. PubMed ID: 34871053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.
    Tso FY; Lidenge SJ; Poppe LK; Peña PB; Privatt SR; Bennett SJ; Ngowi JR; Mwaiselage J; Belshan M; Siedlik JA; Raine MA; Ochoa JB; Garcia-Diaz J; Nossaman B; Buckner L; Roberts WM; Dean MJ; Ochoa AC; West JT; Wood C
    PLoS One; 2021; 16(3):e0247640. PubMed ID: 33661923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.
    Teresa Valenzuela M; Urquidi C; Rodriguez N; Castillo L; Fernández J; Ramírez E
    J Med Virol; 2021 Jul; 93(7):4334-4341. PubMed ID: 33713457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.
    Yang P; Tekwani S; Martin GS
    Ann Intern Med; 2020 Jun; 172(12):JC63. PubMed ID: 32539520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
    Lai R; Zhou T; Xiang X; Lu J; Xin H; Xie Q
    Front Med; 2021 Aug; 15(4):644-648. PubMed ID: 33909259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis.
    Zuo L; Ao G; Wang Y; Gao M; Qi X
    J Infect; 2022 Feb; 84(2):248-288. PubMed ID: 34534563
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.